Hepatocellular Carcinoma, a Unique Tumor with a Lack of Biomarkers
Overview
Affiliations
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Interestingly, the great majority of individuals affected by the tumor have underlying liver disease, therefore narrowing the population to be screened. Still, however, there is a clear lack of blood biomarkers, and surveillance in those at risk is performed by frequent imaging of the liver. A variety of multinational collaborations are currently invested in finding biomarkers for HCC based on liver-produced proteins. A new approach with assessment of peripheral proteins might be necessary for the successful early detection of this malignancy.
Prediagnostic plasma proteomics profile for hepatocellular carcinoma.
Zhang X, Zhao L, Ngo L, Dillon S, Gu X, Lai M J Natl Cancer Inst. 2024; 116(8):1343-1355.
PMID: 38688524 PMC: 11308170. DOI: 10.1093/jnci/djae079.
Assessment of STAT4 Variants and Risk of Hepatocellular Carcinoma in Latin Americans and Europeans.
Ayoub A, Anugwom C, Prieto J, Balderramo D, Ferrer J, Mattos A Cancers (Basel). 2023; 15(18).
PMID: 37760499 PMC: 10527221. DOI: 10.3390/cancers15184530.
Wang C, Shi J, Xu J, Fu Q, Ding Y, Yang J Front Oncol. 2022; 12:815326.
PMID: 35145917 PMC: 8821914. DOI: 10.3389/fonc.2022.815326.
Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge.
Mattos A, Debes J, Dhanasekaran R, Benhammou J, Arrese M, Patricio A World J Hepatol. 2021; 13(9):1107-1121.
PMID: 34630878 PMC: 8473502. DOI: 10.4254/wjh.v13.i9.1107.
Prognostic Value and Potential Immunoregulatory Role of SCARF1 in Hepatocellular Carcinoma.
Patten D, Wilkinson A, ORourke J, Shetty S Front Oncol. 2021; 10:565950.
PMID: 34354939 PMC: 8336907. DOI: 10.3389/fonc.2020.565950.